OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
Georgina Meneses‐Lorente, Stephen Fowler, Elena Guerini, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 1, pp. 68-80
Open Access | Times Cited: 14
Georgina Meneses‐Lorente, Stephen Fowler, Elena Guerini, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 1, pp. 68-80
Open Access | Times Cited: 14
Showing 14 citing articles:
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 762-779
Closed Access | Times Cited: 76
Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 762-779
Closed Access | Times Cited: 76
Entrectinib, a new multi-target inhibitor for cancer therapy
Qinghua Jiang, Mingxue Li, Hua Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112974-112974
Open Access | Times Cited: 51
Qinghua Jiang, Mingxue Li, Hua Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112974-112974
Open Access | Times Cited: 51
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics
Agustos C. Ozbey, Georgina Meneses‐Lorente, Brian Simmons, et al.
Clinical Pharmacokinetics (2025)
Closed Access
Agustos C. Ozbey, Georgina Meneses‐Lorente, Brian Simmons, et al.
Clinical Pharmacokinetics (2025)
Closed Access
Kenichi Umehara, Neil Parrott, Emilie Schindler, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 4, pp. 1130-1140
Closed Access | Times Cited: 3
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug–Drug Interaction and Improving Clinical Practice
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 1, pp. 55-66
Closed Access | Times Cited: 8
Félicien Le Louedec, Florent Puisset, Étienne Chatelut, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 1, pp. 55-66
Closed Access | Times Cited: 8
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Georgina Meneses‐Lorente, Elena Guerini, François Mercier, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 91, Iss. 3, pp. 239-246
Open Access | Times Cited: 5
Georgina Meneses‐Lorente, Elena Guerini, François Mercier, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 91, Iss. 3, pp. 239-246
Open Access | Times Cited: 5
Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells
Alejandro Peralta-García, Mariona Torrens‐Fontanals, Tomasz Maciej Stępniewski, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13592-13592
Open Access | Times Cited: 12
Alejandro Peralta-García, Mariona Torrens‐Fontanals, Tomasz Maciej Stępniewski, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13592-13592
Open Access | Times Cited: 12
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making
Nassim Djebli, Vincent Buchheit, Neil Parrott, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2021) Vol. 46, Iss. 6, pp. 779-791
Closed Access | Times Cited: 11
Nassim Djebli, Vincent Buchheit, Neil Parrott, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2021) Vol. 46, Iss. 6, pp. 779-791
Closed Access | Times Cited: 11
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach
Liangang Chen, Na Yao, Hongjie Yang, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 93, Iss. 2, pp. 107-119
Closed Access | Times Cited: 3
Liangang Chen, Na Yao, Hongjie Yang, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 93, Iss. 2, pp. 107-119
Closed Access | Times Cited: 3
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT ‐1014‐6470 in vitro and in vivo
Marion Anliker‐Ort, Jasper Dingemanse, Stéphane Delahaye, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 7, pp. 1220-1231
Open Access | Times Cited: 2
Marion Anliker‐Ort, Jasper Dingemanse, Stéphane Delahaye, et al.
Clinical and Translational Science (2023) Vol. 16, Iss. 7, pp. 1220-1231
Open Access | Times Cited: 2
Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions
Hang Yin, Zhe Wang, Xin Lv, et al.
Chemico-Biological Interactions (2024) Vol. 395, pp. 111023-111023
Closed Access
Hang Yin, Zhe Wang, Xin Lv, et al.
Chemico-Biological Interactions (2024) Vol. 395, pp. 111023-111023
Closed Access
Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report
Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, et al.
Case Reports in Oncology (2023) Vol. 16, Iss. 1, pp. 1558-1567
Open Access | Times Cited: 1
Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, et al.
Case Reports in Oncology (2023) Vol. 16, Iss. 1, pp. 1558-1567
Open Access | Times Cited: 1
Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells
Alejandro Peralta-García, Mariona Torrens‐Fontanals, Tomasz Maciej Stępniewski, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Alejandro Peralta-García, Mariona Torrens‐Fontanals, Tomasz Maciej Stępniewski, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Interactions médicamenteuses de type pharmacocinétique avec les inhibiteurs d’ALK
Benoı̂t Blanchet
Revue des Maladies Respiratoires Actualités (2023) Vol. 15, Iss. 2, pp. 2S189-2S194
Closed Access
Benoı̂t Blanchet
Revue des Maladies Respiratoires Actualités (2023) Vol. 15, Iss. 2, pp. 2S189-2S194
Closed Access
